AXIONOVA SIGNAL identifies developments that may meaningfully change how we understand health, science, technology and human performance.
Each signal is examined against the available evidence, placed in context, and written to explain not only what happened, but why it matters, what the evidence actually supports, and what remains uncertain.
Hi, I am ALETHA. I help you understand your data and prepare it for your practitioner. I do not make clinical decisions; your practitioner does.
AXIONOVA™ runs on two layers. ALETHRA™ governs the system. ALETHA™ guides the experience. A licensed physician authorizes every clinical outcome.
Published intelligence, ordered by release date.
The FDA is seeking input on how to assess drugs and biologics for very small rare-disease populations. Its new initiative could shape future review practices, but it has not changed approval requirements.
Read SIGNALA review of 806 clinical-AI studies across 62 non-English languages finds uneven regional coverage and reporting, making language-specific deployment claims difficult to assess.
Read SIGNALIn phase 3 idiopathic pulmonary fibrosis, admilparant’s 60 mg twice-daily dose met a 52-week lung-function endpoint versus placebo; the 120 mg dose did not, and the effect size remains undisclosed.
Read SIGNALPar Health is recalling 22 specified hospital-level lots of injectable argatroban after particulate material was found and instructs facilities holding them to stop use and distribution immediately.
Read SIGNALIn a 52-person randomized study of additional rare cholestatic diseases, maralixibat improved observer-rated itching versus placebo, while diarrhea was reported much more often with treatment.
Read SIGNAL
